Given the fact that the response rate substantially varies across tumor types, and similarly, patients with the same malignancy could exhibit different responses when treated with anti-programmed death-1/programmed death-ligand 1 (anti-PD-1/PD-L1) or anti-cytotoxic T lymphocyte antigen 4 (anti-CTLA-4) inhibitions, utilizing biomarkers to identify and select who are more likely to respond and who are unlikely to respond, which further contributes to the patient-stratification, is extensively urgent. The gene discussed is CD274; the disease is neoplasm.